MYC and B-cell non-Hodgkin lymphoma: Treatment with elesclomol-Cu and doxorubicin significantly decreased β-catenin and c-Myc protein levels, while increasing C-Casp3 protein levels in B-cell NHL cell lines (Figure 8C and 8D).